Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
NCT02876302Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in inflammatory breast cancer (IBC), sponsored by Dana-Farber Cancer Institute. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT02876302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876302.